Financials in USD. Standardized financial statements.
A compact view of how SpringWorks Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue? | $191.59M | $5.45M | $6.15M | $0 | $35.00M | $0 | $0 | $0 |
| Revenue Growth? | +3417.3% | -11.4% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $12.55M | $422,000 | $1.90M | $490,000 | $349,000 | $192,000 | $17,328 | $3,182 |
| Gross Profit? | $179.04M | $5.03M | $4.25M | -$490,000 | $34.65M | -$192,000 | -$17,328 | -$3,182 |
| Gross Margin? | +93.4% | +92.3% | +69.2% | 0.0% | +99.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $457.17M | $348.04M | $278.78M | $173.47M | $81.32M | $59.24M | $18.49M | $4.66M |
| Operating Income? | -$278.13M | -$343.01M | -$280.67M | -$173.47M | -$46.32M | -$59.24M | -$18.49M | -$4.66M |
| EBITDA? | -$274.66M | -$341.35M | -$275.52M | -$172.98M | -$45.98M | -$59.05M | -$18.47M | -$4.64M |
| Income Before Tax | -$258.13M | -$325.10M | -$277.42M | -$173.91M | -$45.57M | -$58.31M | -$17.81M | -$4.64M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$2 |
| Net Income? | -$258.13M | -$325.10M | -$277.42M | -$173.21M | -$45.57M | -$58.31M | -$17.81M | -$4.64M |
| EPS? | $-3.48 | $-5.15 | $-5.21 | $-3.59 | $-1.05 | $-1.27 | $-0.80 | $-0.11 |
| Diluted EPS? | $-3.48 | $-5.15 | $-5.21 | $-3.59 | $-1.05 | $-1.27 | $-0.80 | $-0.11 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality